Table of Content

1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders

2. Research Methodology
2.1. Research Process
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Market Dynamics
4.2.1.1. Rising Cancer Prevalence Coupled with Technological Advancements Fueling the Market Growth
4.2.1.2. Supporting Initiatives for Early Cancer Diagnosis and Creating Awareness Driving the Market Growth
4.2.1.3. Growing Adoption and Supporting Initiatives for Precision Cancer Diagnostics Creating Opportunities for the Market Players
4.2.1.4. Insufficiencies in the Implementation of Cancer Screening Programs: A Challenge for Cancer Diagnosis in Europe
4.2.2. Factor Analysis
4.3. Trends
4.4. Regulatory Analysis
4.4.1. Regulatory Analysis for IVD Technologies
4.4.2. Regulatory Analysis for Diagnostic Imaging Devices
4.5. Porter’s Five Forces Analysis: Diagnostic Imaging Technologies for Cancer Screening
4.5.1. Bargaining Power of Buyers
4.5.2. Bargaining Power of Suppliers
4.5.3. Threat of Substitutes
4.5.4. Threat of New Entrants
4.5.5. Degree of Competition
4.6. Porter’s Five Forces Analysis: IVD Technologies for Cancer Screening
4.6.1. Bargaining Power of Buyers
4.6.2. Bargaining Power of Suppliers
4.6.3. Threat of Substitutes
4.6.4. Threat of New Entrants
4.6.5. Degree of Competition
4.7. Pricing Analysis

5. Europe Cancer Diagnostics Market–by Product
5.1. Overview
5.2. In Vitro Diagnostics
5.2.1. IVD Consumables
5.2.1.1. Kits & Assays
5.2.1.2. Reagents
5.2.2. IVD Instruments
5.2.2.1. Sequencers
5.2.2.2. Polymerase Chain Reaction (PCR) Systems
5.2.2.3. Immunoassay Analyzers
5.2.2.4. Microarray Readers
5.2.2.5. Other IVD Instruments
5.2.3. IVD Software & Services
5.3. Diagnostic Imaging
5.3.1. Imaging Instruments
5.3.1.1. Computed Tomography (CT)
5.3.1.2. Mammography
5.3.1.3. Magnetic Resonance Imaging (MRI)
5.3.1.4. Ultrasound
5.3.1.5. Other Imaging Instruments
5.3.2. Imaging Consumables
5.3.2.1. Contrast Agents
5.3.2.2. Syringes & Injectors
5.3.2.3. Contrast Delivery Systems
5.3.2.4. Skin Markers
5.3.2.5. Phantoms
5.3.2.6. Other Imaging Consumables
5.3.3. Imaging Software & Services

6. Europe Cancer Diagnostics Market–by Cancer Type
6.1. Overview
6.2. Breast Cancer
6.3. Lung Cancer
6.4. Colorectal Cancer
6.5. Prostate Cancer
6.6. Other Cancer Types

7. Europe Cancer Diagnostics Market–by End User
7.1. Overview
7.2. Hospitals & Diagnostic Laboratories
7.3. Diagnostic Imaging Centers
7.4. Pharmaceutical & Biotechnology Companies
7.5. Academic & Research Institutes

8. Europe Cancer Diagnostics Market Assessment? by Geography
8.1. Overview
8.2. Germany
8.3. France
8.4. U.K.
8.5. Italy
8.6. Spain
8.7. Switzerland
8.8. Netherlands
8.9. Rest of Europe (RoE)

9. Competition Analysis
9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Market Share Analysis (2023)
9.4.1. Europe Cancer IVD Market Share Analysis (2023)
9.4.1.1. F. Hoffmann-La Roche Ltd (Switzerland)
9.4.1.2. Thermo Fisher Scientific Inc. (U.S.)
9.4.1.3. Illumina, Inc. (U.S.)
9.4.2. Europe Diagnostic Imaging Market Share Analysis (2023)
9.4.2.1. GE Healthcare Technologies Inc. (U.S.)
9.4.2.2. Siemens Healthineers AG (Germany)
9.4.2.3. Hologic, Inc. (U.S.)

10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments, SWOT Analysis)
10.1. F. Hoffmann-La Roche Ltd
10.2. Thermo Fisher Scientific Inc.
10.3. QIAGEN N.V.
10.4. Abbott Laboratories
10.5. Illumina, Inc.
10.6. Siemens Healthineers AG
10.7. GE Healthcare Technologies Inc.
10.8. Hologic, Inc.
10.9. Koninklijke Philips N.V.
10.10. Fujifilm Holdings Corporation
10.11. Canon Medical Systems Corporation
(Note: SWOT Analysis of the Top 6 Companies Will Be Provided)

11. Appendix
11.1. Related Reports



List of Figures

Figure 1 Research Process
Figure 2 Secondary Sources Referenced for this Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown Of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Sizing and Growth for ecast Approach
Figure 7 Europe Cancer Diagnostics Market, by Product, 2024 VS. 2031 (USD Million)
Figure 8 Europe Cancer Diagnostics Market, by Cancer Type, 2024 VS. 2031 (USD Million)
Figure 9 Europe Cancer Diagnostics Market, by End User, 2024 VS. 2031 (USD Million)
Figure 10 Europe Cancer Diagnostics Market, by Country/Region
Figure 11 Impact Analysis of Market Dynamics
Figure 12 Europe: Estimated Number of New Cancer Cases 2020 VS. 2035
Figure 13 Eu Regulatory Pathway - IVDR 2017/746
Figure 14 Porter’s Five forces Analysis
Figure 15 Porter’s Five forces Analysis
Figure 16 Europe Cancer Diagnostics Market, by Product, 2024 VS. 2031 (USD Million)
Figure 17 Europe Cancer Diagnostics Market, by Cancer Type, 2024 VS. 2031 (USD Million)
Figure 18 Number of New Lung Cancer Cases in European Countries, 2022–2030
Figure 19 Number of New Colon Cancer Cases in European Countries, 2022–2030
Figure 20 Number of New Rectal Cancer Cases in European Countries, 2022–2030
Figure 21 Europe Cancer Diagnostics Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 22 Europe: Pharmaceutical Industry R&D Expenditure (2000–2021)
Figure 23 Number of Cancer Cases in European Countries, 2022
Figure 24 Europe Cancer Diagnostics Market, by Country, 2024 Vs. 2031 (USD Million)
Figure 25 Europe Cancer Diagnostics Market: Regional Snapshot
Figure 26 Germany: Number of New Cancer Cases, 2022?2040
Figure 27 France: Number of New Cancer Cases, 2022?2040
Figure 28 U.K.: Number of New Cancer Cases, 2022?2040
Figure 29 Italy: Number of New Cancer Cases, 2022?2040
Figure 30 Italy: Number of Biotechnolgy Firms, 2010?2021
Figure 31 Spain: Healthcare Expenditure, 2017–2021 (USD Million)
Figure 32 Spain: Number of New Cancer Cases, 2022?2040
Figure 33 Switzerland: Number of New Cancer Cases, 2022?2040
Figure 34 Switzerland: Healthcare Expenditure, 2020–2024 (USD)
Figure 35 Netherlands: Number of New Cancer Cases, 2022?2040
Figure 36 Healthcare Expenditures In Belgium, Greece, Austria, and Poland, 2018-2021 (USD Million)
Figure 37 Key Growth Strategies Adopted by Leading Players, 2020– 2024
Figure 38 Europe Cancer In Vitro Diagnostics (IVD) Market: Competitive Benchmarking
Figure 39 Europe Cancer Diagnostic Imaging Market: Competitive Benchmarking
Figure 40 Europe Cancer In Vitro Diagnostics Market Share Analysis, by Key Players, 2023 (%)
Figure 41 Europe Cancer Diagnostics Market Share Analysis for Imaging, by Key Players, 2023 (%)
Figure 42 F. Hoffmann-La Roche Ltd.: Financial Snapshot (2022)
Figure 43 Thermo Fisher Scientific Inc.: Financial Snapshot (2022)
Figure 44 QIAGEN N.V.: Financial Snapshot (2022)
Figure 45 Abbott Laboratories: Financial Snapshot (2022)
Figure 46 Illumina, Inc.: Financial Snapshot (2022)
Figure 47 Siemens Healthineers AG: Financial Snapshot (2023)
Figure 48 GE Healthcare Technologies Inc.: Financial Snapshot (2022)
Figure 49 Hologic, Inc.: Financial Snapshot (2023)
Figure 50 Koninklijke Philips N.V.: Financial Snapshot (2022)
Figure 51 Fujifilm Holdings Corporation: Financial Snapshot (2022)
Figure 52 Canon Medical Systems Corporation (A Subsidiary Of Canon Inc.): Financial Snapshot (2022)